March 2026: Novo Nordisk Slashes Prices, Hims in Regulatory Crisis, and Medicare Coverage on the Horizon
The GLP-1 market is shifting dramatically - Novo Nordisk announces 50% price cuts for 2027, Hims faces lawsuits and SEC investigation, TrumpRx launches, and Medicare coverage nears. Here's what it means for your provider choices.
We’ve completed our March 2026 research update across all 50+ GLP-1 providers. This month brought seismic industry changes that reshape our rankings and how we think about the entire compounded vs. brand-name GLP-1 market.
The Biggest Headlines
Novo Nordisk Announces 50% Price Cuts for 2027
On February 24, 2026, Novo Nordisk announced it will slash U.S. list prices for Wegovy and Ozempic by up to 50%, effective January 1, 2027. The new list price will be approximately $675/month for both medications — a roughly 50% cut for Wegovy and 35% for Ozempic. The cuts also apply to the Wegovy pill and Rybelsus.
What this means: This is the beginning of the end for the compounding price advantage. When brand-name semaglutide drops to $675/mo next year, the gap with compounded options ($99-199/mo) narrows significantly — especially when you factor in FDA approval and quality assurance.
Hims & Hers in Regulatory Crisis
Hims & Hers is facing a “triple threat” that has reshaped our rankings:
- Feb 5: Hims launched a $49/mo compounded oral semaglutide pill
- Feb 6: FDA warned it would restrict mass-marketed compounded GLP-1s
- Feb 7: Hims pulled the oral pill after HHS referred them to the DOJ
- Feb 9: Novo Nordisk sued Hims for patent infringement (US Patent 8,129,343)
- SEC investigation disclosed over compounded semaglutide business disclosures
- Stock down 50%+ since January 2026
Rankings impact: We’ve removed Hims from all “best” rankings this month. While their compounded injectable semaglutide remains available ($199/mo on 6-month plan), the regulatory uncertainty is too significant to recommend them as a top choice.
TrumpRx Platform Goes Live
TrumpRx.gov launched February 6, 2026 as a federal direct-to-consumer platform offering branded GLP-1 medications at reduced prices:
- Wegovy/Ozempic: ~$350/month (down from ~$1,000-1,350)
- Zepbound: ~$350/month (down from ~$1,000+)
- Future oral GLP-1s: $150/month starting dose from either manufacturer
Zepbound KwikPen Launches
LillyDirect launched the Zepbound KwikPen on February 23, 2026 — a multi-dose pen containing 4 doses per pen (one-month supply). Same pricing as vials ($299-449/mo). More convenient than the single-dose vial format.
Medicare GLP-1 Coverage Approaching
Medicare coverage for GLP-1 medications is becoming reality:
- April 2026: Zepbound multi-dose pen covered at $50/mo copay
- Mid-2026: GLP-1 coverage demonstration program at $50/mo copay
- January 2027: Full BALANCE Model for Medicare Part D
- Medicare pricing: $245/mo from manufacturers, $50/mo patient copay
Major Rankings Changes
Who Moved Up
| Provider | Change | Why |
|---|---|---|
| LifeMD | Up across all brand-name rankings | Dual manufacturer partnerships confirmed, lowest national cash-pay pricing |
| Noom Med | Returns to tirzepatide/Zepbound rankings | LillyDirect partnership via Gifthealth confirmed (correcting earlier reports) |
| WeightWatchers Clinic | Up in Wegovy rankings | Post-bankruptcy stability, official Novo partner for Wegovy pill |
| Mochi Health | New to compounded top 5 | Flat-rate pricing at all doses ($99/mo sema + $79/mo membership) |
Who Moved Down
| Provider | Change | Why |
|---|---|---|
| Hims & Hers | Removed from all rankings | Novo Nordisk lawsuit, SEC investigation, DOJ referral, stock crash |
| GoodRx Care | Down in brand-name rankings | Subscription tripled from $39/mo to $119/mo in February 2026 |
Compounding Market Under Siege
The compounded GLP-1 market is facing existential pressure from multiple directions:
- FDA enforcement escalating — announced intent to restrict mass-marketed compounded GLP-1s
- Novo Nordisk suing Hims & Hers, previously terminated partnerships
- Eli Lilly suing Empower Pharmacy, refiled against Strive Pharmacy in Arizona
- HHS referring companies to DOJ for potential criminal violations
- Brand-name prices dropping — Wegovy pill at $149/mo, Zepbound at $299/mo, 50% list cuts in 2027
But compounders are fighting back: Strive Pharmacy filed an antitrust lawsuit against both Eli Lilly and Novo Nordisk in January 2026, alleging coordinated suppression of compounded GLP-1 products.
Provider-Specific Updates
Pricing Changes
| Provider | Semaglutide | Tirzepatide | Key Change |
|---|---|---|---|
| Ro | $45 first mo, $145 ongoing | $299-449/mo (Zepbound) | Wegovy injection intro pricing expires Mar 31 |
| LifeMD | $199/mo intro (branded) | $299-449/mo (Zepbound) | Confirmed lowest national cash-pay pricing |
| Ivim Health | $75/mo + $75/mo membership | $149/mo + $75/mo membership | 34,000+ Trustpilot reviews |
| Mochi Health | $99/mo + $79/mo membership | $199/mo + $79/mo membership | Flat-rate at all doses |
| OrderlyMeds | $74-83/mo (3-mo starter) | N/A | Best trial pricing |
| Lemonaid Health | $129-299/mo (compounded) | $299-449/mo (Zepbound) | New Bambu Ventures ownership |
Regulatory & Legal Updates
- Empower Pharmacy: Eli Lilly lawsuit (July 2025) ongoing. Filed patent invalidation petition. FDA warning letters on record. HIGH regulatory risk.
- Strive Pharmacy: Filed antitrust suit against Lilly + Novo (Jan 2026). Lilly refiled original lawsuit in Arizona.
- Olympia Pharmacy: Remains liraglutide-only. Investing in R&D for other compoundable formulations.
- Brello Health: Shipping delay warning on website as of mid-February 2026.
What This Means for You
If you’re starting fresh: The brand-name market has become dramatically more accessible. With Wegovy pill at $149/mo, Zepbound at $299/mo, and TrumpRx at ~$350/mo, the case for compounded medications is weakening. Consider LifeMD, Ro, or Calibrate for reliable brand-name access.
If you’re currently on compounded GLP-1s: Monitor the regulatory situation carefully. Your provider may face enforcement action. Consider providers like Ro that offer both compounded AND brand-name options so you have a fallback path.
If you’re on Hims: Consider switching to a more stable provider. Ro, LifeMD, or Ivim Health offer comparable compounded pricing with less regulatory risk.
If you’re on Medicare: GLP-1 coverage at $50/mo copay is coming mid-2026. Talk to your doctor now about getting started so you’re ready when coverage begins.
If budget is your priority: Ivim Health ($75/mo + membership), OrderlyMeds ($74-83/mo starter), and Mochi Health ($99/mo + membership) still offer the lowest compounded prices, but consider the total cost including membership fees.
This update reflects our research as of March 1, 2026. Pricing and availability can change — always verify directly with providers before making decisions. Use our provider comparison tool to see the latest details.